IP Library Granted Patent US 8,143,290
Granted Patent B2
US 8,143,290 · App. 12/959,027 · Granted Mar 27, 2012

Chemical compounds 572

Assignees: AstraZeneca AB; Bayer Schering Pharma Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,143,290
App. No.
12/959,027
Granted
Mar 27, 2012
Kind
B2
Abstract

Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.

Claims (13)

1. A compound

or a pharmaceutically acceptable salt thereof.

2. A mixture of N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(6-methoxypyridin-3-yl)propan-2-yl]cyclopropanecarboxamide, or a pharmaceutically acceptable salt thereof; and N-[(1S,2R)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(6-methoxypyridin-3-yl)propan-2-yl]cyclopropanecarboxamide, or a pharmaceutically acceptable salt thereof.

3. The mixture according to claim 2 , wherein the mixture is a racemic mixture.

4. N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(6-methoxypyridin-3-yl)propan-2-yl]cyclopropanecarboxamide, or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 4 , which is N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(6-methoxypyridin-3-yl)propan-2-yl]cyclopropanecarboxamide.

6. The compound according to claim 4 , which is N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(6-methoxypyridin-3-yl)propan-2-yl]cyclopropanecarboxamide in the form of a pharmaceutically acceptable salt.

7. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as claimed in claim 1 , and a pharmaceutically acceptable adjuvant, diluent or carrier.

8. A pharmaceutical composition comprising a mixture as claimed in claim 2 or 3 , and a pharmaceutically acceptable adjuvant, diluent or carrier.

9. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as claimed in claim 4 , and a pharmaceutically acceptable adjuvant, diluent or carrier.

10. A pharmaceutical composition comprising a compound as claimed in claim 5 , and a pharmaceutically acceptable adjuvant, diluent or carrier.

11. A method of treating asthma, which comprises administering to a mammal that has asthma and is in need of treatment for asthma an effective amount of a compound or a pharmaceutically acceptable salt thereof as claimed in claim 1 .

12. A method of treating COPD, which comprises administering to a mammal that has COPD and is in need of treatment for COPD an effective amount of a compound or a pharmaceutically acceptable salt thereof as claimed in claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Sep 30, 2013
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 031315/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2011
From: DAHMEN, JAN; ERIKSSON, ANDERS; GABOS, BALINT; HANSSON, THOMAS; HENRIKSSON, KRISTER; LEPISTO, MATTI; MUNCK AF ROSENSCHOLD, MAGNUS; NILSSON, STINABRITT; HEMMERLING, MARTIN; IVANOVA, SVETLANA; EDMAN, KARL; BERGER, MARKUS; REHWINKEL, HARTMUT; MCKERRECHER, DARREN; TAFLIN, CAMILLA
To: ASTRAZENECA AB; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 025600/0362 →
Continuity (6)
Continuation 12643504 · Dec 21, 2009
Continuation 12005066 · Dec 20, 2007
Provisional Application 60978526 · Oct 9, 2007
Provisional Application 60941745 · Jun 4, 2007
Provisional Application 60871184 · Dec 21, 2006
Related Publication 20110071194A1 · Mar 24, 2011